Physician profile
James Stuart May
NPI 1427468966
$3,703.40
in general payments reported to CMS, 2019-2025
29 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $116 · 2021: $378 · 2022: $484 · 2023: $371 · 2024: $368 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209 · Travel and Lodging: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.90 |
| Travel and Lodging | $963.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $1,073.21 | 2025 | |
| Coopersurgical, INC. | $570.32 | 2019-2023 | Mara Console |
| Abbvie INC. | $445.37 | 2019-2025 | |
| Organon LLC | $216.28 | 2022-2025 | |
| Pfizer INC. | $197.09 | 2019-2024 | |
| Hologic Sales and Service, LLC | $130.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.32 | 2019-2024 | |
| Daiichi Sankyo INC. | $102.18 | 2019-2023 | Injectafer |
| Ethicon US, LLC | $92.75 | 2021 | |
| Astellas Pharma US INC | $87.00 | 2019-2025 | Veozah, Myrbetriq |
| Biogen, INC. | $82.02 | 2024-2025 | Zurzuvae |
| Alydia Health | $81.82 | 2021 | |
| Coloplast Corp | $70.82 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $55.86 | 2019-2024 | Gardasil 9, Gardasil |
| Pacira Pharmaceuticals Incorporated | $53.60 | 2025 | Exparel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $52.44 | 2019-2022 | |
| Amgen INC. | $42.86 | 2020-2022 | |
| Convatec INC. | $35.44 | 2023-2025 | |
| Davol INC. | $29.82 | 2025 | Arista |
| Myovant Sciences INC. | $26.67 | 2022 | |
| Mayne Pharma Commercial LLC | $24.65 | 2023 | |
| Minerva Surgical, INC | $22.78 | 2019 | |
| Inspire Medical Systems, INC. | $17.78 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $17.10 | 2025 | Dupixent |
| Shield Therapeutics INC | $16.30 | 2023 | Accrufer |
| Avion Pharmaceuticals | $15.16 | 2022 | |
| Axonics, INC. | $12.87 | 2022 | |
| Sumitomo Pharma America, INC. | $12.74 | 2023 | Myfembree |
| Mycovia Pharmaceuticals, INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.